Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Price Action

News

Movers

MRUS

Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for petosemtamab in combination with pembrolizumab. 

Merus Shares Are Up Today: What&#39;s Going On?

GE Vernova Benefits from Gas Demand

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

SUNS

TSX:FTS

VKTX

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Why It Matters

BHVN

Merus announced a research collaboration and license agreement with Biohaven.

What&#39;s Going On With Merus Stock Monday?

Merus NV

Press Releases

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Health Care

General

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Merus to Present at Upcoming Investor Conferences

Earnings

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Comments

Merus

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga